Sonoma Pharmaceuticals Unveils New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa
Mar 30, 2022 By MarketDepth
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) has reported launch of Microdox, a urinary tract infection catheter and bladder rinse in New Zealand, Australia and South Africa. “We believe Microdox® is a unique bladder irrigation that fulfils the requirements of an effective adjunct UTI prevention and treatment for the removal of UTI-causing bacteria, bacterial biofilms and drug-resistant strains,” said Scott Lissington, COO of Te Arai BioFarma.
“We look forward to the benefits that Microdox® will offer in the prevention and treatment of urinary tract infections to health care professionals. This is a revolutionary treatment to patients that have been struggling with complicated, antibiotic resistant and recurrent UTIs.”
Lindsay Shahim, Director of NuAngle
“We are pleased to bring our partners this new indication for Microdox® that will help reduce urinary tract infections for their patients. Through the science and development of Microcyn® Technology our aim is to improve the quality of life for patients, including those that require a bladder and catheter rinse,” said Bruce Thornton, COO of Sonoma Pharmaceuticals. “Our proprietary Microcyn® technology is truly the next-generation formulation in terms of superior antimicrobial impact, shelf stability and safety.”
